BioSpace News Archive

Partnership adds Leica’s surgical microscope portfolio to Federal Supply Schedule serving government healthcare facilities

Assembly Biosciences, Inc. announced that clinical data for its lead HBV core inhibitor vebicorvir, its second-generation core inhibitor ABI-H2158, as well as its highly sensitive HBV assays were highlighted during The Digital International Liver Congress™, the Annual Meeting of the European Association for the Study of the Liver.

VK2809-Treated Patients Maintain Durable, Statistically Significant Liver Fat Reductions at Week 16, Four Weeks Following Last Study Dose

Company that uses fish skin to heal human wounds and damaged tissue continues its rapid growth

Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that data from Enanta’s wholly-owned development programs for non-alcoholic steatohepatitis and hepatitis B virus will be presented at the European Association for the Study of the Liver Digital International Liver Congress™ 2020.

Moderna, Inc. confirmed that the Company is engaged in discussions with the Ministry of Health, Labour and Welfare of Japan to potentially purchase 40 million or more doses of mRNA-1273, Moderna’s vaccine candidate against COVID-19, to support Japan’s aim of providing vaccines to the public as soon as possible.

Yiling Pharmaceutical on Thursday published its semiannual report of 2020.

Plus Therapeutics, Inc, announced that it will be presenting at the LD 500 investor conference on Friday, September 4 at 10.20 AM ET.

Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, announced that it will present efficacy and safety data from the CONCERT Phase 2 trial of AXS-12 in the treatment of narcolepsy at the 34th Annual SLEEP Meeting of the Associated Professional Sleep Societies.

CollPlant, a regenerative and aesthetics medicine company, announced financial results for the second quarter ended June 30, 2020 and provided an update on the Company’s business developments.